| 1 |
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie, Andreas H. Diacon, Nosipho Ngubane et al. · New England Journal of Medicine
Open access |
4 Mar 2020 |
1,079 |
| 2 |
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Dereck R. Tait et al. · New England Journal of Medicine
Open access |
29 Oct 2019 |
623 |
| 3 |
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas Henri Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · The Lancet
|
22 Jul 2012 |
440 |
| 4 |
Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Olivier Van Der Meeren et al. · New England Journal of Medicine
Open access |
25 Sep 2018 |
425 |
| 5 |
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin Johan Boeree, Andreas Henri Diacon, Rodney Dawson et al. · American Journal of Respiratory and Critical Care Medicine
Open access |
5 Feb 2015 |
320 |
| 6 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson, Andreas Henri Diacon, Daniel E. Everitt et al. · The Lancet
Open access |
23 Mar 2015 |
251 |
| 7 |
Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
Andreas Henri Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · American Journal of Respiratory and Critical Care Medicine
|
26 Jan 2015 |
202 |
| 8 |
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
Andreas Henri Diacon, Rodney Dawson, Madeleine Hanekom et al. · Antimicrobial Agents and Chemotherapy
Open access |
25 May 2010 |
177 |
| 9 |
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Florian von Groote-Bidlingmaier et al. · The Lancet Respiratory Medicine
Open access |
8 Jan 2019 |
169 |
| 10 |
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Conor Tweed, Rodney Dawson, Divan Aristo Burger et al. · The Lancet Respiratory Medicine
Open access |
12 Nov 2019 |
150 |
| 11 |
Telacebec (Q203), a New Antituberculosis Agent
Veronique R. De Jager, Rodney Dawson, Christo van Niekerk et al. · New England Journal of Medicine
Open access |
25 Mar 2020 |
142 |
| 12 |
Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824
Andreas Henri Diacon, Rodney Dawson, Jeannine du Bois et al. · Antimicrobial Agents and Chemotherapy
Open access |
20 Mar 2012 |
138 |
| 13 |
β-Lactams against Tuberculosis — New Trick for an Old Dog?
Andreas Henri Diacon, Lize van der Merwe, Marinus Barnard et al. · New England Journal of Medicine
Open access |
14 Jul 2016 |
128 |
| 14 |
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
Kelly E. Dooley et al. · The Lancet Infectious Diseases
Open access |
15 Feb 2021 |
125 |
| 15 |
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial
Tracey A. Day et al. · The Lancet Respiratory Medicine
|
8 Dec 2020 |
108 |
| 16 |
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis
Ahmed Aliyu Abulfathi, Eric H. Decloedt, Elin M. Svensson et al. · Clinical Pharmacokinetics
|
2 May 2019 |
108 |
| 17 |
Patient satisfaction with health care providers in South Africa: the influences of race and socioeconomic status
Neil G. Myburgh, Geetesh C. Solanki, Matthew James Smith et al. · International Journal for Quality in Health Care
Open access |
28 Jun 2005 |
107 |
| 18 |
Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis
Andreas Henri Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier et al. · Antimicrobial Agents and Chemotherapy
Open access |
5 Mar 2013 |
99 |
| 19 |
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
Norbert Heinrich et al. · Journal of Antimicrobial Chemotherapy
Open access |
27 Jan 2015 |
94 |
| 20 |
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
Caryn M. Upton, Rob Christiaan van Wijk, Laurynas Mockeliūnas et al. · EClinicalMedicine
Open access |
12 May 2022 |
91 |
| 21 |
Novel drugs against tuberculosis: a clinician's perspective
Ioana Diana Olaru, Florian von Groote-Bidlingmaier, Jan Heyckendorf et al. · European Respiratory Journal
Open access |
27 Nov 2014 |
90 |
| 22 |
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Ildikó Madurka et al. · Infection
Open access171 authors |
14 Sep 2022 |
87 |
| 23 |
A Comparative Study of Features for Acoustic Cough Detection Using Deep Architectures
Igor D. S. Miranda, Andreas Henri Diacon, Thomas Niesler
Conference paper |
Jul 2019 |
87 |
| 24 |
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
Conor Tweed, Genevieve H. Wills, Angela M. Crook et al. · BMC Medicine
Open access |
28 Mar 2018 |
79 |
| 25 |
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Patrick P. J. Phillips, Carl M. Mendel, Divan Aristo Burger et al. · BMC Medicine
Open access |
4 Feb 2016 |
78 |
| 26 |
Clofazimine pharmacokinetics in patients with TB: dosing implications
Mahmoud Tareq Abdelwahab, Sean A Wasserman, James C.M. Brust et al. · Journal of Antimicrobial Chemotherapy
Open access |
24 Jun 2020 |
73 |
| 27 |
C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial
Henrik Aggerbeck, Morten Rühwald, Soren Tetens Hoff et al. · PLoS ONE
Open access |
24 Sep 2018 |
71 |
| 28 |
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier et al. · American Journal of Respiratory and Critical Care Medicine
Open access |
16 Jan 2020 |
70 |
| 29 |
Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878–1940
Peter Roderick Donald, Andreas Henri Diacon, Christoph G. Lange et al. · The International Journal of Tuberculosis and Lung Disease
|
10 Aug 2018 |
69 |
| 30 |
Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents
Andreas Henri Diacon, J. S. Maritz, Amour Venter et al. · Clinical Microbiology and Infection
Open access |
30 Jun 2011 |
69 |
| 31 |
Intensive adherence counselling for HIV‐infected individuals failing second‐line antiretroviral therapy in Johannesburg, South Africa
Matthew P. Fox, Rebecca H. Berhanu, Kim Steegen et al. · Tropical Medicine & International Health
|
7 Jul 2016 |
68 |
| 32 |
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
Conor Tweed et al. · The International Journal of Tuberculosis and Lung Disease
Open access |
25 Mar 2021 |
65 |
| 33 |
Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations
Robin J. Svensson, Elin M. Svensson, Rob E. Aarnoutse et al. · The Journal of Infectious Diseases
Open access |
24 Apr 2018 |
63 |
| 34 |
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Müge Çevik et al. · The Lancet Infectious Diseases
Open access |
17 May 2024 |
62 |
| 35 |
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1rifampicin
Lindsey H. M. te Brake, Veronique R. De Jager, Kim Narunsky et al. · European Respiratory Journal
Open access |
4 Feb 2021 |
61 |
| 36 |
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
Andreas Henri Diacon, Clifton E. Barry, Alex Carlton et al. · Nature Medicine
Open access |
16 Feb 2024 |
56 |
| 37 |
The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis
Alison S. Devonshire et al. · BMC Infectious Diseases
Open access |
3 Aug 2016 |
55 |
| 38 |
Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis
Christoph G. Lange et al. · Journal of Internal Medicine
Open access |
28 May 2018 |
49 |
| 39 |
A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid
Koné Kaniga, Daniela María Cirillo, Sven Erik Hoffner et al. · Journal of Clinical Microbiology
Open access |
21 Sep 2016 |
49 |
| 40 |
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Yingda L. Xie et al. · Science Translational Medicine
Open access |
3 Feb 2021 |
48 |
| 41 |
A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing
Koné Kaniga, Daniela María Cirillo, Sven Erik Hoffner et al. · Journal of Clinical Microbiology
Open access |
21 Sep 2016 |
48 |
| 42 |
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
Ray Y. Chen et al. · Gates Open Research
Open access |
6 Nov 2017 |
45 |
| 43 |
Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens
Andreas Henri Diacon, Lize van der Merwe, Anne‐Marie Demers et al. · Tuberculosis
|
18 Dec 2013 |
44 |
| 44 |
Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis
Ray Y. Chen et al. · The Lancet Microbe
Open access |
6 Jul 2021 |
42 |
| 45 |
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
Patrick P. J. Phillips, Kelly E. Dooley, Stephen H. Gillespie et al. · BMC Medicine
Open access |
22 Mar 2016 |
42 |
| 46 |
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Andreas Henri Diacon, Veronique R. De Jager, Rodney Dawson et al. · Antimicrobial Agents and Chemotherapy
Open access |
23 Jan 2020 |
40 |
| 47 |
A clinical practice guideline for tuberculous meningitis
Joseph Donovan et al. · The Lancet Infectious Diseases
Open access |
19 Aug 2025 |
39 |
| 48 |
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease
Amita Gupta et al. · Clinical Infectious Diseases
Open access |
26 Mar 2019 |
39 |
| 49 |
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study
Conor Tweed, Angela M. Crook, Evans Amukoye et al. · BMC Infectious Diseases
Open access |
11 Jul 2018 |
39 |
| 50 |
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)
Caryn M. Upton, Chanel I Steele, Gary Maartens et al. · Journal of Antimicrobial Chemotherapy
Open access |
23 Feb 2022 |
35 |